Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study
- 16 July 2017
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 32 (12) , 2445-2452
Abstract
: Our objective was to examine whether adjunct teriparatide administration and local application of recombinant human bone morphogenetic protein-2 (rhBMP-2) is beneficial for the regeneration of jaw bone in patients with medication-related osteonecrosis of the jaw (MRONJ). This study enrolled 17 patients diagnosed with MRONJ. All patients received sequestrectomy under general or local anesthesia with suspension of bisphosphonate. The bone regeneration ratio was compared on cone beam computed tomography (CBCT) scans, acquired immediately post-operation and after 6 months. The patients were divided into groups, based on their treatment regimens: teriparatide combined with rhBMP-2 (parathyroid hormone [PTH]+BMP), rhBMP-2 (BMP), and the control. Biochemical markers were also evaluated at the baseline (T0), 1 month (T1), and 3 months (T2) after surgery. Significant increase was observed in the values of the biochemical markers, serum osteocalcin, and serum C-terminal telopeptide cross-link of type I collagen, within 3 months of surgery in the PTH+BMP group, whereas the mean value in the BMP group did not show a significant change. In all groups, the MRONJ lesions were healed and new bone formation was detected in the CBCT images. The regeneration ratio was significantly greater in the group PTH+BMP than in the BMP and control groups. Significantly greater amount of bone formation was observed in the group PTH+BMP than in the BMP and control groups. Local application of rhBMP-2 alone also had a beneficial effect on bone regeneration but was not more significant than control. Based on these findings, administration of short-term teriparatide with rhBMP-2 in MRONJ patients may maximize the regeneration of bone after surgery. © 2017 American Society for Bone and Mineral Research.Keywords
Funding Information
- Korea Health Technology R&D project
This publication has 16 references indexed in Scilit:
- Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jawsOsteoporosis International, 2012
- Nationwide Survey for Bisphosphonate-Related Osteonecrosis of the Jaws in JapanJournal of Oral and Maxillofacial Surgery, 2011
- Successful treatment of advanced bisphosphonate‐related osteonecrosis of the mandible with adjunctive teriparatide therapyHead & Neck, 2011
- Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?Clinical Oral Implants Research, 2010
- The Role of Surgical Resection in the Management of Bisphosphonate-Related Osteonecrosis of the JawsJournal of Oral and Maxillofacial Surgery, 2009
- Stimulation of Fracture-Healing with Systemic Intermittent Parathyroid Hormone TreatmentJournal of Bone and Joint Surgery, 2008
- Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and TreatmentJournal of Oral and Maxillofacial Surgery, 2007
- Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone StructureJournal of Bone and Mineral Research, 2003
- New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1–34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized RatsEndocrinology, 2003
- Bone Repair Following Recombinant Human Bone Morphogenetic Protein‐2 Stimulated Periodontal RegenerationJournal of Periodontology, 2002